Market Closed -
Nasdaq
01:30:00 02/05/2024 am IST
|
5-day change
|
1st Jan Change
|
72.73
USD
|
+1.28%
|
|
-0.53%
|
+1.55%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,896
|
2,549
|
4,264
|
5,012
|
6,893
|
7,678
|
-
|
-
|
Enterprise Value (EV)
1 |
1,672
|
1,892
|
3,850
|
4,418
|
6,393
|
6,923
|
6,839
|
6,569
|
P/E ratio
|
-12.8
x
|
-9.85
x
|
-15
x
|
-19.5
x
|
-49.1
x
|
-116
x
|
64.3
x
|
18.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
31,282
x
|
112
x
|
50.9
x
|
20
x
|
14.8
x
|
11.6
x
|
8.32
x
|
5.77
x
|
EV / Revenue
|
27,586
x
|
82.9
x
|
45.9
x
|
17.7
x
|
13.8
x
|
10.5
x
|
7.41
x
|
4.94
x
|
EV / EBITDA
|
-10.9
x
|
-8.2
x
|
-13.5
x
|
-16.8
x
|
-40.2
x
|
-85.8
x
|
66.2
x
|
16.7
x
|
EV / FCF
|
-13.1
x
|
-9.32
x
|
-14.8
x
|
-16.3
x
|
-51.4
x
|
-205
x
|
35.2
x
|
13.6
x
|
FCF Yield
|
-7.66%
|
-10.7%
|
-6.75%
|
-6.13%
|
-1.95%
|
-0.49%
|
2.84%
|
7.33%
|
Price to Book
|
9.77
x
|
3.9
x
|
10.2
x
|
7.65
x
|
11.6
x
|
7.31
x
|
6.33
x
|
4.24
x
|
Nbr of stocks (in thousands)
|
55,261
|
80,158
|
81,463
|
94,705
|
96,238
|
1,05,571
|
-
|
-
|
Reference price
2 |
34.31
|
31.80
|
52.34
|
52.92
|
71.62
|
72.73
|
72.73
|
72.73
|
Announcement Date
|
02/03/20
|
25/02/21
|
01/03/22
|
01/03/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.0606
|
22.81
|
83.8
|
250.3
|
464.4
|
661.6
|
922.7
|
1,330
|
EBITDA
1 |
-153.5
|
-230.7
|
-285.2
|
-263
|
-158.9
|
-80.73
|
103.4
|
392.7
|
EBIT
1 |
-154
|
-231.2
|
-285.7
|
-263.6
|
-159.4
|
-81.95
|
92.04
|
427.2
|
Operating Margin
|
-2,54,103.04%
|
-1,013.58%
|
-340.9%
|
-105.32%
|
-34.32%
|
-12.39%
|
9.98%
|
32.11%
|
Earnings before Tax (EBT)
1 |
-147.7
|
-227
|
-284.1
|
-256.2
|
-139
|
-61.64
|
126.5
|
488.2
|
Net income
1 |
-147.7
|
-227
|
-284.1
|
-256.3
|
-139.7
|
-59.54
|
108.3
|
388.9
|
Net margin
|
-2,43,725.75%
|
-995.07%
|
-339.04%
|
-102.37%
|
-30.08%
|
-9%
|
11.74%
|
29.23%
|
EPS
2 |
-2.680
|
-3.230
|
-3.500
|
-2.720
|
-1.460
|
-0.6273
|
1.131
|
3.890
|
Free Cash Flow
1 |
-128.1
|
-203.1
|
-259.9
|
-271
|
-124.5
|
-33.75
|
194.4
|
481.6
|
FCF margin
|
-2,11,341.63%
|
-890.12%
|
-310.1%
|
-108.25%
|
-26.8%
|
-5.1%
|
21.07%
|
36.21%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
188.07%
|
122.63%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
179.48%
|
123.85%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/03/20
|
25/02/21
|
01/03/22
|
01/03/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
22.21
|
25.67
|
35
|
55.58
|
71.87
|
87.87
|
95.31
|
110.8
|
126.2
|
132.1
|
141.3
|
159.4
|
172.5
|
187.3
|
184.2
|
EBITDA
1 |
-77.07
|
-85.86
|
-72.49
|
-87.75
|
-55.46
|
-47.27
|
-48.26
|
-47.06
|
-29.58
|
-33.96
|
-35.5
|
-26.6
|
-19.15
|
-6.05
|
-
|
EBIT
1 |
-77.32
|
-86
|
-72.66
|
-87.92
|
-55.63
|
-47.41
|
-48.39
|
-47.18
|
-29.71
|
-34.1
|
-34.16
|
-23.91
|
-17.49
|
-9.784
|
-25.8
|
Operating Margin
|
-348.19%
|
-335.03%
|
-207.63%
|
-158.19%
|
-77.4%
|
-53.96%
|
-50.78%
|
-42.58%
|
-23.55%
|
-25.81%
|
-24.17%
|
-15%
|
-10.14%
|
-5.22%
|
-14.01%
|
Earnings before Tax (EBT)
1 |
-76.93
|
-85.73
|
-72.11
|
-86.6
|
-53.51
|
-44.03
|
-44.04
|
-42.65
|
-24.22
|
-28.13
|
-30.1
|
-19.64
|
-12.52
|
-0.9374
|
-20.4
|
Net income
1 |
-76.91
|
-85.73
|
-72.12
|
-86.6
|
-53.51
|
-44.03
|
-44.05
|
-42.78
|
-24.26
|
-28.58
|
-31.69
|
-20.77
|
-11.41
|
0.0763
|
-20.4
|
Net margin
|
-346.32%
|
-333.97%
|
-206.08%
|
-155.82%
|
-74.45%
|
-50.1%
|
-46.22%
|
-38.62%
|
-19.23%
|
-21.63%
|
-22.42%
|
-13.03%
|
-6.62%
|
0.04%
|
-11.07%
|
EPS
2 |
-0.9500
|
-1.050
|
-0.7800
|
-0.9200
|
-0.5700
|
-0.4500
|
-0.4600
|
-0.4500
|
-0.2500
|
-0.3000
|
-0.3267
|
-0.2082
|
-0.1125
|
0.002760
|
-0.2000
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
01/03/22
|
10/05/22
|
09/08/22
|
03/11/22
|
01/03/23
|
04/05/23
|
03/08/23
|
02/11/23
|
22/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
224
|
657
|
414
|
594
|
500
|
755
|
839
|
1,109
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-128
|
-203
|
-260
|
-271
|
-124
|
-33.7
|
194
|
482
|
ROE (net income / shareholders' equity)
|
-57.6%
|
-53.3%
|
-52.9%
|
-47.7%
|
-22.4%
|
-9.19%
|
6.53%
|
24.4%
|
ROA (Net income/ Total Assets)
|
-48.6%
|
-46.9%
|
-47.1%
|
-41.2%
|
-18.8%
|
-9.23%
|
-5.39%
|
8.81%
|
Assets
1 |
304.2
|
484.3
|
603.6
|
622.4
|
741.4
|
644.8
|
-2,011
|
4,414
|
Book Value Per Share
2 |
3.510
|
8.160
|
5.140
|
6.920
|
6.170
|
9.940
|
11.50
|
17.20
|
Cash Flow per Share
2 |
-2.320
|
-3.270
|
-3.190
|
-2.870
|
-1.300
|
-0.3000
|
1.330
|
3.450
|
Capex
1 |
0.7
|
0.27
|
0.33
|
0.78
|
0.27
|
1.95
|
2.64
|
4.23
|
Capex / Sales
|
1,155.58%
|
1.17%
|
0.39%
|
0.31%
|
0.06%
|
0.29%
|
0.29%
|
0.32%
|
Announcement Date
|
02/03/20
|
25/02/21
|
01/03/22
|
01/03/23
|
22/02/24
|
-
|
-
|
-
|
Last Close Price
72.73
USD Average target price
90.28
USD Spread / Average Target +24.13% Consensus |
1st Jan change
|
Capi.
|
---|
| +1.55% | 7.68B | | -3.80% | 86.16B | | +2.76% | 40.17B | | -16.48% | 31.47B | | +57.86% | 25.24B | | -13.58% | 15.82B | | -9.12% | 11.96B | | -42.56% | 11.61B | | +6.89% | 8.84B | | -3.16% | 7.93B |
Biopharmaceuticals
|